Setback to Johnson and Johnson: Maha FDA cancels baby powder manufacturing license

Samples of the powder for babies did not conform to standard pH value during a laboratory test, the regulator said.

The release said the action was taken after Kolkata-based Central Drugs Laboratory's conclusive report that concludes "the sample does not conform to IS 5339:2004 with respect to the test for pH." According to the release, FDA had drawn samples of Johnson's Baby Powder from Pune and Nashik for quality check purposes.

Read also: Mired in controversy, JNJ baby powder to go off shelves from 2023

The government analyst had declared the samples as "not of the standard quality" as they do not comply with IS 5339:2004 specification for skin powder for infants in the test pH, it said.

Thereafter, FDA issued a show-cause notice to Johnson and Johnson under the Drugs Cosmetics Act 1940 and Rules, besides issuing instructions to the company to recall the stock of the said product from market, said the release.

Read also: Johnson and Johnson puts newly created subsidiary into bankruptcy over baby powder claims

The firm "didn't accept the report" of the government analyst and challenged it in court for sending it to the Central Drugs Laboratory, it added. 

Medical Dialogues team had earlier reported that the Maharashtra FDA had registered an offense against Amazon for selling Abortion Drugs on line allegedly illegally. The Assistant Commissioner of FDA Ganesh Rokade stated that the Food and Drugs Administration had observed that abortion drugs were being sold illegally on online portals through the internet.

Read also: E-Pharmacy giant Amazon under Maha FDA radar for selling MTP kits without prescription